Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy
-
Add time:09/09/2019 Source:sciencedirect.com
Ursodeoxycholic acid (cas 128-13-2) (UDCA) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. UDCA is also a long-established drug, largely used for the dissolution of cholesterol gallstones, the treatment of primary biliary cholangitis and other hepatobiliary disorders. The history of UDCA is briefly retraced here as well as its multifactorial mechanism of action, based on its anti-inflammatory, antioxidant and cytoprotective activities. The present review is centred around the anticancer properties of UDCA and synthetic antitumor derivatives designed over the past 20 years. Paradoxically, depending on the conditions, UDCA exhibits both pro- and anti-apoptotic properties toward different cell types. In particular, the UDCA drug can protect epithelial cells from damages and apoptosis while inducing inhibition of proliferation and apoptotic and/or autophagic death of cancer cells. The effects of UDCA on cancer cell migration, cancer stem cells and drug-induced dysbiosis are also evoked. The drug has revealed modest activities against colon and gastric cancers but may be useful to improve treatments of hepatocellular carcinoma, notably in combination with other drugs such as sorafenib. UDCA can also protect from damages induced by cancer chemotherapeutic agents. The potential of UDCA in cancer, as a chemo-protecting or chemotherapeutic agent, is highlighted here as well as the design of tumour-active derivatives, including UDCA-drug conjugates. A repurposing of UDCA in oncology should be further considered.
We also recommend Trading Suppliers and Manufacturers of Ursodeoxycholic acid (cas 128-13-2). Pls Click Website Link as below: cas 128-13-2 suppliers
Prev:Chemical reaction of hydrogenated diamond surface with amino acids by using N-Chlorosuccinimide (cas 128-09-6)
Next:Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis09/28/2019
- Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity10/01/2019
- Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH09/27/2019
- Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)09/26/2019
- ArticlesUrsodeoxycholic acid (cas 128-13-2) versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial09/25/2019
- Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease09/24/2019
- Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis09/10/2019
-
Health and Chemical more >